

GLAXOSMITHKLINE PLC

Form 6-K

January 15, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 15 January 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
Chief Executive Officer
- b) Position/status

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- Ordinary shares of 19 pence each ('Ordinary Shares')
- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £15.3600 | 199       |
| £15.3600 | 216       |
| £15.3600 | 758       |
| £15.3600 | 199       |
| £15.3600 | 216       |

Aggregated information

- d)
- |                   |          |
|-------------------|----------|
| Aggregated volume | 1,588    |
| Price             | £15.3600 |

- e) Date of the transaction 2019-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Vaccines

- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 19 pence each ('Ordinary Shares')
- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.3600 | 135       |
|                           | £15.3600 | 113       |
|                           | £15.3600 | 161       |
|                           | £15.3600 | 113       |

- Aggregated information
- d) Aggregated volume Price

522  
£15.3600

- e) Date of the transaction 2019-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S P Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/  
amendment Initial notification
- 2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.3600 | 263       |
|                           | £15.3600 | 197       |
|                           | £15.3600 | 537       |
|                           | £15.3600 | 263       |
|                           | £15.3600 | 197       |

Aggregated information

- d) Aggregated volume Price 1,457  
£15.3600

- e) Date of the transaction 2019-01-11  
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons  
b) Position/status SVP, Global Ethics & Compliance

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 19 pence each ('Ordinary Shares')	
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c) Price(s) and volume(s)	Price(s)      Volume(s)
	£15.3600      97
	£15.3600      71
	£15.3600      84
	£15.3600      97
	£15.3600      71
Aggregated information	
d)	
Aggregated volume	420
Price	£15.3600
e) Date of the transaction	2019-01-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr B McNamara CEO, GSK Consumer
b) Position/status	Healthcare

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares ('ADSs')	
	ISIN: US37733W1053	
b) Nature of the transaction	Increase in notional interest in American Depositary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on American Depositary Shares held in the Company's Deferred Annual Bonus Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	\$ 39.3600	82
	\$ 39.3600	80
d) Aggregated information		
Aggregated volume Price	162	\$39.3600
e) Date of the transaction	2019-01-11	
f) Place of the transaction	New York Stock Exchange (XNYS)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr L Miels
b) Position/status	President, Global Pharmaceuticals

c) Initial notification/ amendment	Initial notification
------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 19 pence each ('Ordinary Shares')	
	ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of	

dividends paid to  
shareholders on 10 January  
2019 on Ordinary Shares held  
in the Company's Deferred  
Annual Bonus Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.3600	153
	n/a (single transaction)	

Aggregated information

d) Aggregated volume Price

e) Date of the transaction	2019-01-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 19 pence each ('Ordinary Shares') ISIN: GB0009252882
--	---

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Performance Share Plan.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.3600	124
	£15.3600	90
	£15.3600	156

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£15.3600	124
£15.3600	90

Aggregated information

d) Aggregated volume Price

584  
£15.3600

e) Date of the transaction

2019-01-11

f) Place of the transaction

London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Ms K Terrell  
Chief Digital & Technology  
Officer

b) Position/status

c) Initial notification/  
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument

American Depositary Shares  
(‘ADSs’)  
ISIN: US37733W1053

b) Nature of the transaction

Increase in notional interest  
in American Depositary  
Shares following the  
re-investment of dividends  
paid to shareholders on 10  
January 2019 on American  
Depositary Shares held in the  
Company's Deferred Annual  
Bonus Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
\$ 39.3600	27

d) Aggregated information

n/a (single transaction)

Aggregated volume Price



e) Date of the transaction 2019-01-11  
 f) Place of the transaction New York Stock Exchange  
 (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 19 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest  
 in Ordinary Shares following  
 the re-investment of  
 dividends paid to  
 shareholders on 10 January  
 2019 on Ordinary Shares held  
 in the Company's Deferred  
 Annual Bonus Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£15.3600	181
	£15.3600	135
	£15.3600	170
	£15.3600	181
	£15.3600	135

Aggregated information

d) Aggregated volumePrice  
 802£15.3600

e) Date of the transaction 2019-01-11  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr P C Thomson
  - b) Position/status President, Global Affairs
  - c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 19 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£15.3600	111
£15.3600	85
£15.3600	106
  - d) Aggregated information
 

Aggregated volume Price	302 £15.3600
-------------------------	-----------------
  - e) Date of the transaction 2019-01-11
  - f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 15, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc